Company: NCEL
Filing Date: 2025-04-04
Form Type: 6-K/A
Source: 0001213900-25-028988
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-04-04
Form: 6-K/A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K/A

(Amendment No. 1)

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of March 2025 (Report No. 2)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

On March 31, 2025, NLS
Pharmaceutics Ltd, or the Company, filed a Form 6-K, or the Original 6-K, related to a private placement financing transaction in the
amount of $3 million. This amendment on Form 6-K/A amends and restates the Original 6-K to add disclosure about a common share purchase
warrant in the Offering (as defined below) and to add the common share purchase warrant as an exhibit.

Private Placement Financing Transaction in the amount of $3 million

On March 27, 2025, the Company
entered into a securities purchase agreement, or the Securities Purchase Agreement, with three accredited investors. Pursuant to the terms
of the Securities Purchase Agreement, the Company agreed to issue and sell to the investors, in a private placement offering, or the Offering,
(i) 1,212,122 preferred shares, par value CHF 0.03 per share, or the Preferred Shares, with a conversion price of $1.65 per share, (ii)
common share purchase warrants, or the Common Warrants, to purchase 787,879 common shares, par value CHF 0.03 per share, for aggregate
gross proceeds of $2 million. The Common Warrants have a term of five years and have an exercise price of $1.80 per share. Pursuant
to the terms of the Securities Purchase Agreement, the investors may purchase up to $1 million of additional Preferred Shares on identical
terms as the initial closing, subject to the Company obtaining